Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vomiting 3Nausea 3Leukemia 2Hematologic Neoplasms 2Lymphoma 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1

Interventions

Cyclophosphamide 13fludarabine 11Mycophenolic Acid 9Busulfan 8fludarabine phosphate 7Tacrolimus 7pirtobrutinib 6Whole-Body Irradiation 6Rituximab 6Melphalan 6Imatinib Mesylate 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Granulocyte Colony-Stimulating Factor 4Azacitidine 4venetoclax 3nilotinib 3lintuzumab 3Stem Cell Transplantation 3Sirolimus 3Platelet Transfusion 3Methotrexate 3Cytarabine 3Cyclosporine 3Alemtuzumab 3vosaroxin 2ruxolitinib 2ibrutinib 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Palonosetron × Other hematologic neoplasm × Clear all
NCT01031498 2012-08-07

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

M.D. Anderson Cancer Center

Phase 2 Completed
150 enrolled 7 charts
Other hematologic neoplasm

Hematologic Diseases, Leukemia, Nausea, Vomiting, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡